Matthias D'Huyvetter

4PUBLICATIONS
27CO-AUTHORS
Molecular targetsRadiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Dec 13, 2025
Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib.

Jonatan Dewulf, Laurent Navarro, Nina Dumauthioz

|Aug 01, 2025
Immune modulation following α and β- radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model.

Hannelore Ceuppens, Kirsten De Ridder, Thomas Ertveldt

|Sep 21, 2022
Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.

Magdalena Rodak, Yana Dekempeneer, Maria Wojewódzka

|May 02, 2022
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.

Thomas Ertveldt, Lien De Beck, Kirsten De Ridder

Pageof 1

Frequent Collaborators

2 joint publications

Thomas Ertveldt

2 joint publications

Tony Lahoutte

2 joint publications

Kirsten De Ridder

2 joint publications

Wout de Mey